Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Axitinib - Pfizer

Next Previous
X
Search
Drug Profile

Axitinib - Pfizer

Alternative Names: AG-013736; AG-13,736; Inlyta

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Grupo Espanol de Tumores Neuroendocrinos; H. Lee Moffitt Cancer Center and Research Institute; Merck Sharp & Dohme; Netherlands Cancer Institute; Pfizer; Royal Marsden Hospital; SCRI Development Innovations; SFJ Pharmaceuticals; Sheffield Teaching Hospitals NHS Foundation Trust; University of Cincinnati; University of Texas M. D. Anderson Cancer Center; University of Wisconsin-Madison
  • Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal cell carcinoma
  • Phase II/III Neuroendocrine tumours
  • Phase II Carcinoid tumour; Colorectal cancer; Endometrial cancer; Glioblastoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Soft tissue sarcoma; Urogenital cancer
  • No development reported Solid tumours
  • Discontinued Breast cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer; Thyroid cancer

Most Recent Events

  • 26 Apr 2024 Abramson Cancer Center of the University of Pennsylvania in collaboration with Pfizer terminates a phase I trial in Colorectal cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in USA (PO) due to failure in enrollment (NCT04873895)
  • 05 Jun 2023 Pfizer in collaboration with MD Anderson cancer center completes a phase-II clinical trials in Renal cell carcinoma (Neoadjuvant therapy, Late-stage disease) in USA (PO) (NCT01263769)
  • 02 Jun 2023 Efficacy data from phase II trial in Endometrial cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top